[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353455-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353455-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-proteinsmall-molecule-conjugate-as-a-bispecific-inhibitor-of-proteases-implicated-in-cancer-metastasis","A protein–small molecule conjugate as a bispecific inhibitor of proteases implicated in cancer metastasis","","Matrix metalloproteinase-9 (MMP-9) and kallikrein 6 (KLK6) are key extracellular proteases that promote metastatic progression in colorectal and pancreatic cancers, where overexpression associates with aggressive disease and poor prognosis. Monospecific inhibition shows limited efficacy, while dual inhibition has remained largely unexplored. Using click chemistry, the study builds a bispecific inhibitor by conjugating an MMP-9-targeting N-TIMP2 (with propargyl lysine) to the KLK6 inhibitor DKFZ-938. In vitro assays show dose-dependent suppression of migration and invasion in multiple cancer cell lines without reducing viability, outperforming monospecific inhibitors and combinations. ",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-proteinsmall-molecule-conjugate-as-a-bispecific-inhibitor-of-proteases-implicated-in-cancer-metastasis/353455/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-proteinsmall-molecule-conjugate-as-a-bispecific-inhibitor-of-proteases-implicated-in-cancer-metastasis/353455.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are MMP-9 and KLK6 considered therapeutic targets for cancer metastasis?","Question",{"text":63,"@type":64},"They are extracellular proteases implicated in metastatic progression, and their overexpression in colorectal and pancreatic cancers correlates with aggressive disease and poor prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the bispecific inhibitor constructed?",{"text":68,"@type":64},"It was prepared via site-specific click chemistry by conjugating an MMP-9-selective N-TIMP2 bearing propargyl lysine to the small molecule KLK6 inhibitor DKFZ-938, yielding N-TIMP2PrK–DKFZ-938.",{"name":70,"@type":61,"acceptedAnswer":71},"What effects did the bispecific inhibitor have on cancer cells?",{"text":72,"@type":64},"Functional assays in HCT-116, PANC-1, and CAPAN-2 cells showed dose-dependent inhibition of migration and invasion, outperforming the corresponding monospecific inhibitors without affecting cell viability.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353455,1790194477,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nA protein–small molecule conjugate as a bispecific inhibitor of proteases implicated in cancer metastasis  \nInbar Bahat1,4, Yuval Pinkert1,4, Andreas Baumann2, Eyal Arbely3, Aubry K. Miller2 & Niv Papo1  \nMatrix metalloproteinase-9 (MMP-9) and kallikrein 6 (KLK6) are key extracellular proteases implicated in metastatic progression. In colorectal and pancreatic cancers, their overexpression correlates with aggressive disease and poor prognosis, making them attractive therapeutic targets. While monospecific inhibition of either protease shows limited efficacy, simultaneous dual inhibition has not yet been explored as a strategy to block metastasis. To address the lack of an efficient inhibitor of the above metastatic cancers, we prepared a bispecific inhibitor by the site-specific conjugation, via click chemistry, of a selective inhibitor of MMP-9 to a small molecule specifically inhibiting KLK6; the inhibitor comprised the N-terminal domain of tissue inhibitor of metalloproteinases 2 (N-TIMP2), bearing the non-canonical amino acid propargyl lysine (PrK), conjugated to a small molecule known as DKFZ-938. The bispecific inhibitor, thus designated N-TIMP2PrK–DKFZ-938, exhibited inhibitory activity against purified KLK6 and both purified and cellular MMP9 in the absence and presence of  \nKLK6 . Functional assays ofthe bispecific inhibitor in HCT-116, PANC-1, and CAPAN-2 cancer cell lines expressing both MMP-9 and KLK6 demonstrated dose-dependent inhibition of migration and invasion that outperformed the respective monospecific inhibitors, alone or in admixture, without affecting cell viability. These results thus show N-TIMP2PrK–DKFZ-938 to be a promising dual-targeting therapeutic prototype, providing simultaneous inhibition of two proteases that cooperatively drive metastasis.  \nKeywords Bi-specific inhibitor, TIMP, MMP, KLK, DKFZ-938, Non-canonical amino acids, Click chemistry, Migration, Invasion  \nAbbreviations  \nADC Antibody-drug conjugate  \nBGU Ben-Gurion University of the Negev  \nCy5.5-Az Cyanine5.5 azide ECM Extracellular matrix  \nFBS Fetal bovine serum  \nKLK Kallikrein  \nMMP Matrix metalloproteinase MMP-9CAT Catalytic domain of MMP-9 ncAA Non-canonical amino acid  \nPrK Propargyl lysine  \nTIMP Tissue inhibitor of matrix metalloproteinase SD Standard deviation  \nSEM Standard error of the mean  \n1Avram and Stella Department of Biotechnology Engineering and The National Institute of Biotechnology, BenGurion University of the Negev, P.O. Box 653, Beer-Sheva 84105, Israel. 2Cancer Drug Development, German Cancer Research Center (DKFZ), Heidelberg, Germany. 3Department of Chemistry, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 84105, Israel. 4These authors contributed equally: Inbar Bahat andYuval Pinkert.  \nemail: [papo@bgu.ac.il](papo@bgu.ac.il)  \n[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nPancreatic1 and colorectal2,3 cancers are highly aggressive malignancies with poor prognosis and limited treatment options. In these cancers, membrane-anchored receptors and soluble extracellular proteases act in concert to drive tumor progression, invasion, and metastasis4–7. Their cooperative activity in the tumor microenvironment creates challenges for effective therapy, as inhibition of a single target alone (i.e., monospecific therapy) often fails to fully suppress the cooperative metastatic processes driven by such pairs of molecular targets8–12.  \nWith the aim to overcome the limitations of monospecific therapies for pancreatic and colorectal cancers, research is currently being devoted to developing combination therapies and bispecific inhibitors targeting multiple pathways. For pancreatic cancer, bispecific strategies are showing encouraging preclinical efficacy. For example, a TNF-related apoptosis-inducing ligand (TRAIL) receptor 2/cadherin-3 (TRAILR2/CDH3) bispecific antibody selectively induced apoptosis ","cbCaichDJAaNawaW","https://ap.wps.com/l/cbCaichDJAaNawaW","pdf",2243351,13,"English","# Background\n## Rationale for dual targeting\n# Bispecific inhibitor design\n## Conjugation strategy and construct\n# Experimental evaluation\n## Enzymatic inhibition\n## Cell-based functional assays\n## Comparison with monospecific inhibitors\n# Implications for therapy","[{\"question\":\"Why are MMP-9 and KLK6 considered therapeutic targets for cancer metastasis?\",\"answer\":\"They are extracellular proteases implicated in metastatic progression, and their overexpression in colorectal and pancreatic cancers correlates with aggressive disease and poor prognosis.\"},{\"question\":\"How was the bispecific inhibitor constructed?\",\"answer\":\"It was prepared via site-specific click chemistry by conjugating an MMP-9-selective N-TIMP2 bearing propargyl lysine to the small molecule KLK6 inhibitor DKFZ-938, yielding N-TIMP2PrK–DKFZ-938.\"},{\"question\":\"What effects did the bispecific inhibitor have on cancer cells?\",\"answer\":\"Functional assays in HCT-116, PANC-1, and CAPAN-2 cells showed dose-dependent inhibition of migration and invasion, outperforming the corresponding monospecific inhibitors without affecting cell viability.\"}]","A protein–small molecule conjugate as a bispecific inhibitor of proteases implicated in cancer metastasis | PDF",1790105514,33,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f101318a8efdcfe9a606526fcbcf54a4.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/703b9ccb2b73922bcc3f57cbf0bb635a.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96537d7f01d9ad9da0af8e2b95e9531d.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb5ef08317f3706915f31ec1ed342b89.webp",980,1287]